was further validated today. Say what you want, but Glaxo's data was going to be scrutinized by the street. The fact that this Exon skipping technology has been further validated (even in it's broadest interpretation), bodes well for SRPT.
I guess you beat me to it, kg. Just catching up here!
Glaxo could never start phase 3 if it knew Sarepta's data.